Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
Date:2/28/2013

SAN FRANCISCO, Feb. 28, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2012.

Cash, cash equivalents, and investments at December 31, 2012 were $302.2 million as compared to $414.9 million at December 31, 2011.

"As we enter 2013, Nektar is in an excellent position with five highly valuable late-stage programs across multiple therapeutic areas," said Howard W. Robin, President and Chief Executive Officer of Nektar. "With positive efficacy and safety results from the full Phase 3 KODIAC program for naloxegol, our partner AstraZeneca is preparing to submit registration filings in the U.S. and EU in the third quarter of this year.  We are tremendously pleased that Bayer is scheduled to start the Phase 3 program next month for Amikacin Inhale in gram-negative pneumonia.  Additionally, we expect to report key Phase 2 clinical data this summer for NKTR-181, our novel opioid analgesic, which represents a potential breakthrough for the treatment of chronic pain."

Revenue for the fourth quarter of 2012 was $21.1 million as compared to $15.8 million in the fourth quarter of 2011. Revenue for the year ended December 31, 2012 was $81.2 million as compared to $71.5 million in 2011.  2012 revenue included $10.8 million in non-cash revenues resulting from the $124 million sale of future royalties related to Cimzia® and Mircera®, which was completed in February 2012.  This non-cash royalty revenue is offset by non-cash interest expense.  For both the quarter and the year ended December 31, 2012, product sales increased significantly.  These increases were partially offset by decreases in royalty revenues.

Total operating costs and expenses in the fourth quarter of 2012 were $64.5 million as compared to $50.3 million in the fourth
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
2. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
3. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
8. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Calif., Oct 21 MAP Pharmaceuticals, Inc. (Nasdaq: ... of Thomas P. McCracken as Vice President, Intellectual ... property program in support of the potential commercialization ... inhaled migraine therapy, and other product opportunities. ...
... (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer ... Backer, Ph.D., to the newly-created position of senior vice ... all aspects of chemistry, manufacturing and controls (CMC) in ... pipeline products. "We are extremely pleased to ...
Cached Medicine Technology:MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property 2MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property 3Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations 2
(Date:4/23/2014)... a researcher from the Cancer Science Institute of Singapore ... identified the cancer specific stem cell which causes gastric ... new drugs for the treatment of this disease and ... by Dr Chan Shing Leng, Research Assistant Professor at ... cancer-specific variant of a cell surface protein, CD44v8-10, marks ...
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... may prevent the depletion of self-control, according to research ... the Association for Psychological Science. , Self-control can be ... focus attention on a boring textbook are hard things ... this difficulty: Exerting self-control for a long period seems ... subsequent tasks. , "It is as if self-control is ...
(Date:4/23/2014)... Getting to the bottom of Alzheimer,s disease has ... turns and controversies. In the latest crook in ... insight into the interaction between proteins associated with ... journal ACS Chemical Neuroscience , could have ... K. Surewicz, Krzysztof Nieznanski and colleagues explain that ...
(Date:4/22/2014)... visited the New Jersey Institute of Technology (NJIT) ... for the launch of the New Jersey Innovation ... new model for business innovation through the leveraging ... investment. U.S. Senator Cory Booker, Panasonic Corp. of ... Jersey Lieutenant Governor Kim Guadagno, New Jersey Secretary ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... Instead of dismissing grumblings about being tired or exhausted, ... to a worsened health state or even death, says ... ,Dr. Karin Olson, a U of A professor from ... between tiredness, fatigue and exhaustion and that recognizing those ...
... study has found that a brief session of muscle-building exercise ... response.// ,The immune system’s reaction differs markedly between ... process remains unclear. ,“We’re trying to find ... benefit your vaccine response,” said lead author Kate Edwards, Ph.D., ...
... in the United States over age 20 are affected ... from the Johns Hopkins Bloomberg School of Public Health. ... age, cardiovascular disease, diabetes and a lack of physical ... lifestyle changes, such as increased physical activity and measures ...
... is a condition resulting from inflammation of joints. ... movement.// ,Spondylarthritis (SpA), ankylosing spondylitis (AS), ... all associated rheumatic diseases collectively known as "spondyloarthropathies".,Aside ... by ankylosis, stiffness and fusion of bone in ...
... which the bone mass in the body becomes reduced// and ... normally affects postmenopausal women. ,A McMaster University researcher ... a woman's problem but that the bone-wasting disease can severely ... professor of clinical medicine, and a group of five Canadian ...
... brain cell came from remain distinct even after the cell ... will report in the February 1 issue of Cancer Research. ... complexity to the quest to understand the causes of childhood ... Ph.D., the Donald O. Schnuck Family Professor of Neurology at ...
Cached Medicine News:Health News:Take Fatigue Seriously - Says Researcher 2Health News:Take Fatigue Seriously - Says Researcher 3Health News:Muscle-Building Exercise Improves Response to Flu Shot 2Health News:More Than 18 Million US Men Affected by ED 2Health News:Does Anti-TNF Therapy Control Ankylosis ? 2Health News:Osteoporosis Does Not Spare Men Either 2Health News:Genetic Fingerprints Identify Brain Tumors' Origins 2
... Vibratome Semi-Automatic Tissue Sectioning System has maintained ... sectioning system. Researchers from around the globe ... for their fresh and fresh fixed tissue ... With the Vibratome Automatic Tissue Sectioning ...
... 1500 Sectioning System provides a versatile means ... plant tissues. The 1500 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effect ...
... Semi-Automatic Tissue Sectioning System has maintained the ... system. Researchers from around the globe have ... their fresh and fresh fixed tissue sectioning ... With the Vibratome Automatic Tissue Sectioning Systems, ...
... The NEW Vibratome 3000 Plus Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
Medicine Products: